Title: Role of Adenosine Deaminase and Insulin in Type 2 Diabetes Mellitus in Eastern India
Authors: Ravela Malathi, Chandra Narayan Gupta, Anindita Banerjee, Pradip Kumar Agrawal, Vineet Kumar Khemka, Vijay Raghavan
DOI: https://dx.doi.org/10.18535/jmscr/v5i4.123
Abstract
Background & Objectives: Adenosine plays a crucial role in bioactivity of insulin and regulates insulin activity in type 2 diabetes mellitus (T2DM). The aim of our study was to study the altered levels of adenosine deaminase and its association with insulin in T2DM.
Methods: The The preliminary case-control study included age, sex and body mass index (BMI) matched 68 T2DM cases and 52 healthy control subjects. Serum ADA was measured using a spectrophotometer while fasting serum levels of insulin was measured by commercially available immunoassay kits and routine biochemical parameters were analyzed in all study groups.
Results: Serum ADA level was found significantly higher among T2DM subjects with respect to controls (38.77 ± 14.29 versus 17.02 ± 5.74 U/L; P < 0.0001). An increase in serum insulin levels were also observed in T2DM cases as compared to controls and were statistically significant (17.28 ± 6.71 versus 10.33 ± 3.89 U/L; P < 0.0001). Serum ADA level showed a significant positive correlation with fasting plasma glucose (r = 0.324; P = 0.007) level among non-obese T2DM subjects, but no significant correlation was observed in controls (r = 0.071; P = 0.615).
Conclusion: The high level of serum ADA suggests that it may be used as a prognostic marker for the pathogenesis of T2DM.
Keywords: Diabetes Mellitus, Adenosine deaminase, Insulin, Insulin resistance.
References
1. Sheetz MJ, King GL. Molecular understanding of hyperglycemia’s adverse effects for diabetic complications. JAMA 2002; 288: 2579-88.
2. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995–2025: prevalence, numerical estimates, and projections. Diabetes Care 1998; 21: 1414–1431.
3. Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27: 1047-53.
4. Allen DW, Schroeder WA,Balog. Observation on the chromatographic heterogenicity of normal adult and fetalHb: a study of the effect of crystallization and chromatography as the heterogenicity and isoleucine content. Am J ChemSoc 1958; 80: 1628-34.
5. Vaag A, Lund SS. Non-obese patients with type 2 diabetes and prediabetic subjects: distinct phenotypes requiring special diabetes treatment and (or) prevention? Applied Physiology, Nutrition and Metabolism 2007;32(5):912–920.
6. Prakash MS, Chennaiah S, Murthy YSR, Anjaiah E, Rao SA, Suresh C. Altered adenosine deaminase activity in type 2 diabetes mellitus. Journal, Indian Academy of Clinical Medicine 2006;7(2):114–117.
7. Khemka VK, Bagchi D, Ghosh A, et al. Raised Serum Adenosine Deaminase Level in Nonobese Type 2 Diabetes Mellitus. ScientificWorldJournal. 2013; 2013: 404320.
8. Espinal J., John Challiss R. A., Newsholme E. A. Effect of adenosine deaminase and an adenosine analogue on insulin sensitivity in soleus muscle of the rat. FEBS Letters 1983;158(1):103–106.
9. McLane M. P., Black P. R., Law W. R., Raymond R. M. Adenosine reversal of in vivo hepatic responsiveness to insulin. Diabetes. 1990;39(1):62–69.
10. Hoshino T., Yamada K., Masuoka K., et al. Elevated adenosine deaminase activity in the serum of patients with diabetes mellitus. Diabetes Research and Clinical Practice. 1994;25(2):97–102.
11. Johansson S. M., Lindgren E., Yang J.-N., Herling A. W., Fredholm B. B. Adenosine A1 receptors regulate lipolysis and lipogenesis in mouse adipose tissue—interactions with insulin. European Journal of Pharmacology. 2008;597(1–3):92–101.
12. Vannucci SJ, Nishimura H, Satoh S, Cushman SW, Holman GD, Simpson IA. Cell surface accessibility of GLUT4 glucose transporters in insulin-stimulated rat adipose cells. Modulation by isoprenaline and adenosine. Biochemical Journal. 1992;288(1):325–330.
13. Zavialov A. V., Yu X., Spillmann D., Lauvau G., Zavialo A. V. Structural basis for the growth factor activity of human adenosine deaminase ADA2. Journal of Biological Chemistry. 2010;285(16):12367–12377.
14. Warrier A. C., Rao N. Y., Kulpati D. S., Mishra T. K., Kabi B. C. Evaluation of adenosine deaminase activity and lipid peroxidation levels in diabetes mellitus. Indian Journal of Clinical Biochemistry. 1995;10(1):9–13.
15. Giusti G, Galanti B. Colorimetric method. Adenosine deaminase. In: Bergmeyer HU, editor. Methods of Enzymatic Analysis. 3rd edition. Weinheim, Germany: VerlagChemie; 1984;315–323.
16. van der Weyden MB, Kelley WN. Human adenosine deaminase. Distribution and properties. The Journal of Biological Chemistry. 1976;251(18):5448–5456.
17. Vergauwen L, Hespel P, Richter EA. Adenosine receptors mediate synergistic stimulation of glucose uptake and transport by insulin and by contractions in rat skeletal muscle. The Journal of Clinical Investigation. 1994;93(3):974–981.
18. Mills S. E. Regulation of porcine adipocyte metabolism by insulin and adenosine. Journal of Animal Science. 1999;77(12):3201–3207
19. Vannucci S. J., Nishimura H., Satoh S., Cushman S. W., Holman G. D., Simpson I. A. Cell surface accessibility of GLUT4 glucose transporters in insulin-stimulated rat adipose cells. Modulation by isoprenaline and adenosine. Biochemical Journal. 1992;288(1):325–330.
20. Johansson SM, Lindgren E, Yang J-N, Herling AW, Fredholm BB. Adenosine A1 receptors regulate lipolysis and lipogenesis in mouse adipose tissue—interactions with insulin. European Journal of Pharmacology. 2008;597(1–3):92–101.
21. Takasuga S, Katada T, Ui M., Hazeki O. Enhancement by adenosine of insulin-induced activation of phosphoinositide 3-kinase and protein kinase B in rat adipocytes. The Journal of Biological Chemistry. 1999;274(28):19545–19550.
22. Apasov SG, Blackburn MR, Kellems RE, Smith PT, Sitkovsky MV. Adenosine deaminase deficiency increases thymic apoptosis and causes defective T cell receptor signaling. The Journal of Clinical Investigation. 2001;108(1):131–141.
23. Poliani PL, Vermi W, Facchetti F. Thymus microenvironment in human primary immunodeficiency diseases. Current Opinion in Allergy and Clinical Immunology. 2009;9(6):489–495.
24. Sauer AV, Brigida I, Carriglio N, Aiuti A. Autoimmune dysregulation and purine metabolism in adenosine deaminase deficiency. Frontiers in Immunology. 2012;3:265.
25. Lee JG, Kang DG, Yu JR, et al. Changes in adenosine deaminase activity in patients with type 2 diabetes mellitus and effect of DPP-4 inhibitor treatment on ADA activity. Diabetes and Metabolism Journal. 2011;35(2):149–158.
26. Pickup J. C., Crook M. A. Is type II diabetes mellitus a disease of the innate immune system? Diabetologia. 1998;41 (10):1241–1248.
27. Morohoshi M., Fujisawa K., Uchimura I., Numano F. Glucose-dependent interleukin 6 and tumor necrosis factor production by human peripheral blood monocytes in vitro. Diabetes. 1996;45(3):954–959.
28. Cordero OJ, Salgado FJ, Fernández-Alonso CM, et al. Cytokines regulate membrane adenosine deaminase on human activated lymphocytes. Journal of Leukocyte Biology. 2001;70(6):920–930.
29. Rutkiewicz J, Gorski J. On the role of insulin of regulation of adenosine deaminase activity in rat tissues. FEBS Letters. 1990;271(1-2):79–80.
30. Lee JG, Kang DG, Yu JR, et al. Changes in adenosine deaminase activity in patients with type 2 diabetes mellitus and effect of DPP-4 inhibitor treatment on ADA activity. Diabetes and Metabolism Journal. 2011;35(2):149–158.
31. Hoshino T, Yamada K, Masuoka K, et al. Elevated adenosine deaminase activity in the serum of patients with diabetes mellitus. Diabetes Research and Clinical Practice. 1994;25(2):97–102.
32. Gowda MNV, Vasudha KC, Reshma S, Sujatha KJ. Serum Adenosine deaminase activity in type 2 diabetes mellitus patients. International Journal of Diabetes in Developing Countries. 2012;32(3):176–181.